CoChat

Cabotegravir Plus Rilpivirine: First Approval

Markham, A. · 2020 · Drugs

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the treatment of HIV-1 infection in adults to replace current antiretroviral therapy in patients who are virologically stable and suppressed. This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-020-01326-8

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Research works printed but not linked: 2

  1. Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study [abstract no.34]. In: Conference on Retroviruses and Opportunistic Infections. 2020.
  2. Orkin C. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results [abstract no. 482-PS]. In: Conference on Retroviruses and Opportunistic Infections. 2020.

Cited by

See all 55

Metadata

Authors
Markham, A.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Markham, A.
Venue
Drugs
Published
2020-06
Volume
80
Issue
9
Pages
915-922
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3031948545
Cited by
54
References
13
Citations by year
2026: 2 · 2025: 4 · 2024: 8 · 2023: 17 · 2022: 13 · 2021: 9 · 2020: 1
FWCI
1.34
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
cabotegravir, rilpivirine, HIV-1 infection, antiretroviral therapy, long-acting injectables, drug approval, ATLAS trial
MeSH terms
Rilpivirine, Adult, Drug Therapy, Combination, Humans, Molecular Conformation, Pyridones, HIV-1, HIV Infections, Drug Approval, Anti-HIV Agents, Diketopiperazines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabotegravir Plus Rilpivirine: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01326-8
The paper
Markham, A. (2020). Cabotegravir Plus Rilpivirine: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01326-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.